Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568009 · ClinicalTrials.gov registry record
Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function
A clinical trial, sponsored by Solvay Pharmaceuticals.
- Terminated
- Registry status
- 300
- Enrollment target
NCT00568009: Clinical Trial study, sponsored by Solvay Pharmaceuticals.
NCT00568009 is a clinical trial that was terminated before completion, run by Solvay Pharmaceuticals. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568009 was terminated before completion, sponsored by Solvay Pharmaceuticals.
- TERMINATED
- Registry status
- 300 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily). A total of 50 subjects will be randomized to each increasing dose level of SLV320 or placebo in a sequential fashion.
Interventions
- DRUG SLV320
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-11 |
Why NCT00568009 stopped before completion
NCT00568009 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which SLV320 is the first listed.
NCT00568009 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00568009 about?
NCT00568009 is a clinical study titled "Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function". This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily). A total of 50 subjects will be randomized to each increasing dose level of...
What is the current status of trial NCT00568009?
This trial is currently terminated. The enrollment target is 300 participants. The study started on 2007-10. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00568009?
The interventions under investigation include: SLV320 (DRUG).
Who is sponsoring clinical trial NCT00568009?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia